Dr. John Cush RheumNow
3 years 11 months ago
Is PMR the Next Indication for Tocilizumab?
About half of patients with steroid-dependent PMR were able to get off steroids altogether when they were started on tocilizumab (Actemra) infusions, a randomized phase III trial showed.
https://t.co/fe8d6LNMOh https://t.co/RLhnaEPOVK
Dr. John Cush RheumNow
3 years 11 months ago
This week it's the great and not-so-great on gout, chondrocalcinosis, osteoporosis and misdiagnosis. We are good at many of those things - what's not so great? Let's review the news and journal reports from the past week on RheumNow.
https://t.co/8hICpPVC8b https://t.co/GDHaBb6fFC
Dr. John Cush RheumNow
3 years 11 months ago
A Rheum & Derm Conversation on Treating PsA and Moderate-to-Severe PsO
Sponsored by Lilly USA
Listen to Drs Mease and Armstrong discuss a multidisciplinary approach and important considerations when treating patients with joint and skin concerns. https://t.co/ZAVA83QNa3
Dr. John Cush RheumNow
3 years 11 months ago
2 open-label reports of JAK inhibitors in Systemic sclerosis (SSc) - 59 SSc pts: significant decr in mRSS in 88%. 28/29 w/ ILD had no progression. Overall responses better in treatment naïve SSc patients. 20% had side-effects. More studies needed https://t.co/JtaBxVjoak https://t.co/k34P6SjC6L
Dr. John Cush RheumNow
3 years 11 months ago
Proposed modified SRI (SLE Responder Index) - Reduction in SLEDAI-2K ≥4 (w/ no worsening in MD global (PGA) ≥0.3). mSRI responders had signif lower Dz activity & pred dose, More LLDAS & remission, less damage accrual (p<0.001) https://t.co/lwsZpnRz3l https://t.co/V7pDYswM7b
Dr. John Cush RheumNow
3 years 11 months ago
Five Senses of Medicine - nice graphic download on Clinical Skils (from Annals of Internal Medicine) https://t.co/zeA0bK2Xpe https://t.co/vCasZmRaOY
Dr. John Cush RheumNow
3 years 11 months ago
Interesting read on "The art of paying attention"
Narrative medicine: "attention, representation, and affiliation"
“noticing the words we usually ignore”
“taking the temperature of the conversation.”
“meta-questions”, like “How are we doing so far? https://t.co/Pvx2GOQTgd https://t.co/wswf7Enaie
Dr. John Cush RheumNow
3 years 11 months ago
Be wary when you seen new drugs described as “cutting edge,” “game changing,” and “ground breaking” - as this is more likely advertising than reality. https://t.co/oB9xDFqCg6 https://t.co/wfVyR0P4bS
This week it's the great and not-so-great on gout, chondrocalcinosis, osteoporosis and misdiagnosis. We are good at many of those things - what's not so great? Let's review the news and journal reports from the past week on RheumNow.
An online survey of random COVID-19 infected persons shows that arthralgia and myalgia are common consequences to COVID-19 infection.
Dr. John Cush RheumNow
3 years 11 months ago
RCT of allopurinol in 183 #gout pts. After 6.5 yrs 30% (60) were dead. Survivors 82% Rx w allopurinol, 4% febuxostat, 8% not on ULT. Urate levels only available in 72%!! & only 58% achieved SU T2T <6 mg/dl (<0.36 mmol/L) Dont you think we should do better? https://t.co/NwS6I2A9M8 https://t.co/xvarJQJG2N
Dr. John Cush RheumNow
3 years 11 months ago
Joint Flares extend disease & show joint specific memory. Study of 95 JIA pts, 12.5 yrs F/U: 95% got to inactive dz, 81% flared 1+ times. 74% flares in prior joints, usual side 83%, contralateral 17%, 40% new Jt; more likely off meds https://t.co/20UEtZXUIW https://t.co/yDt7WXvkB0
Dr. John Cush RheumNow
3 years 11 months ago
Uncommon Misdiagnosis of Rheumatoid Arthritis
Using long-term patient data from the BARFOT study of early RA patients, researchers at the Karolinska Institute have shown that use of the ACR-1987 classification criteria was highly precise.
https://t.co/aHI0KW35Q2 https://t.co/Nk0vRNGYBI
The Lasker Foundation has announced the winners of its 2022 Lasker Awards, widely regarded as America’s top biomedical research prize since its creation more than 75 years ago. Here's a look at the award winners and their important contributions to biomedical research.
